Headquarters: Osaka, Japan
Founded: 2023 (Osaka University spin-out)
Focus: BDNF mimetics for Alzheimer's disease
Website: https://www.osakaneuro.jp
Osaka NeuroTherapeutics (ONT) is an Osaka University spin-out company developing brain-derived neurotrophic factor (BDNF) mimetic compounds for the treatment of Alzheimer's disease and related dementias. The company's approach addresses the well-documented decline in BDNF signaling that occurs early in Alzheimer's disease pathogenesis, proposing that restoring BDNF/TrkB signaling can protect vulnerable neurons and support cognitive function[1].
BDNF is the most abundant neurotrophin in the central nervous system and is critical for neuronal survival, synaptic plasticity, and memory formation. Multiple studies have demonstrated reduced BDNF expression in the hippocampus and cortex of Alzheimer's disease patients, and experimental models show that BDNF deficiency accelerates amyloid pathology and cognitive decline[2]. Osaka NeuroTherapeutics was founded to translate these findings into disease-modifying therapies.
BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, a tyrosine kinase that is the primary mediator of BDNF's neurotrophic effects[3]. Upon ligand binding, TrkB dimerizes and autophosphorylates, activating downstream signaling cascades:
These pathways converge to promote synaptic spine formation, enhance long-term potentiation (LTP), support dendritic arborization, and protect neurons against excitotoxic and oxidative stress[3:1].
Multiple mechanisms contribute to reduced BDNF signaling in Alzheimer's disease:
Osaka NeuroTherapeutics is pursuing multiple approaches to restore BDNF/TrkB signaling:
Non-peptidic TrkB agonists that bind and activate the receptor represent an attractive therapeutic approach. Unlike BDNF itself (which cannot cross the BBB), small molecule agonists can be administered orally and achieve adequate CNS exposure[4].
Peptide fragments of BDNF that retain receptor-binding and activation activity offer a middle ground between full proteins and small molecules. These peptides can be optimized for stability and brain penetration while maintaining the key functional domains[5].
Viral vector delivery of BDNF to specific brain regions (particularly the hippocampus and basal forebrain) provides sustained local expression of the neurotrophin.
Target: TrkB agonist
Stage: Lead optimization
Indication: Alzheimer's disease (mild cognitive impairment to mild dementia)
ONT-301 is a small molecule TrkB agonist with optimized pharmacokinetics for CNS penetration. Preclinical data demonstrate:
Target: BDNF mimetic peptide
Stage: Hit-to-lead
Indication: Alzheimer's disease, vascular dementia
ONT-302 is a cyclic peptide that mimics the receptor-binding interface of BDNF. The peptide is being optimized for stability and brain penetration through various peptide delivery strategies.
Osaka NeuroTherapeutics' work intersects with key mechanisms in NeuroWiki:
Osaka NeuroTherapeutics. Company Profile - BDNF Mimetics for Alzheimer's Disease. 2024. ↩︎
Garcia ML, et al. Brain-derived neurotrophic factor deficiency in Alzheimer's disease. Journal of Alzheimer's Disease. 2022. ↩︎ ↩︎
Lu B, et al. BDNF/TrkB signaling in synaptic plasticity and memory. Nature Reviews Neuroscience. 2023. ↩︎ ↩︎
Fenner BM, et al. Small molecule TrkB agonists for neurotrophic therapy. ACS Chemical Neuroscience. 2023. ↩︎
Pang P, et al. Design of BDNF mimetic peptides for CNS disorders. Biopolymers. 2022. ↩︎